Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study to evaluate safety and efficacy of transitioning therapy from alendronate [alendronic acid] to denosumab (AMG 162) in postmenopausal women with low bone mineral density

X
Trial Profile

A randomized study to evaluate safety and efficacy of transitioning therapy from alendronate [alendronic acid] to denosumab (AMG 162) in postmenopausal women with low bone mineral density

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms STAND
  • Sponsors Amgen
  • Most Recent Events

    • 20 Oct 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 18 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
    • 11 Jun 2009 Results published as an abstract in the proceedings of the 91st Annual Meeting of the Endocrine Society (ENDO 2009).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top